S. Fustik (Skopje, North Macedonia), A. Zwitserloot (Groningen, Netherlands)
“Early” Pseudomonas aeruginosa colonization in cystic fibrosis patients
E. OCAK (ANKARA, Turkey), G. Tugcu (ANKARA, Turkey), S. Eryilmaz Polat (ANKARA, Turkey), G. Cinel (ANKARA, Turkey), N. Emiralioglu (ANKARA, Turkey), E. Yalçin (ANKARA, Turkey), N. Kiper (ANKARA, Turkey), V. Sen (DIYARBAKIR, Turkey), D. Altintas (ADANA, Turkey), H. Çokugras (ISTANBUL, Turkey), A. Ayzit Kilinç (ISTANBUL, Turkey), H. Yazan (ISTANBUL, Turkey), G. Ünal (KONYA, Turkey), A. I?mran Yilmaz (KONYA, Turkey), E. Damadoglu (ANKARA, Turkey), I. Irmak (ANKARA, Turkey), E. Demir (IZMIR, Turkey), G. Öztürk (IZMIR, Turkey), A. Basaran (ANTALYA, Turkey), A. Bingöl (ANTALYA, Turkey), N. Sapan (BURSA, Turkey), A. Aslan (ANKARA, Turkey), P. Asfuroglu (ANKARA, Turkey), K. Harmanci (ESKISEHIR, Turkey), M. Köse (KAYSERI, Turkey), M. Hangül (KAYSERI, Turkey), A. Özdemir (MERSIN, Turkey), G. Özcan (ANKARA, Turkey), Z. Gayretli Aydin (TRABZON, Turkey), Ö. Keskin (GAZIANTEP, Turkey), H. Yüksel (MANISA, Turkey), S. Özdogan (ISTANBUL, Turkey), E. Topal (MALATYA, Turkey), G. Çaltepe (SAMSUN, Turkey), D. Can (BALIKESIR, Turkey), P. Korkmaz Ekren (IZMIR, Turkey), M. Kiliç (ELAZIG, Turkey), T. Sismanlar Eyüboglu (ANKARA, Turkey), S. Pekcan (KONYA, Turkey), N. Çobanoglu (ANKARA, Turkey), E. Çakir (ISTANBUL, Turkey), U. Özçelik (ANKARA, Turkey), D. Dogru Ersöz (ANKARA, Turkey)
|  |
Respiratory outcomes at 6 months follow up after SARS-Cov-2 infection in people with cystic fibrosis
P. Medino (Milano, Italy), C. Rosazza (Milano, Italy), M. Boraso (Verona, Italy), F. Ciciriello (Roma, Italy), M. Cipolli (Verona, Italy), A. Gramegna (Milano, Italy), V. Lucidi (Roma, Italy), A. Biffi (Milano, Italy), E. Nazzari (Milano, Italy), G. Alicandro (Milano, Italy), C. Colombo (Milano, Italy)
|  |
The concentration of hCAP-18/LL-37 and hBD-2 in cystic fibrosis patients
O. Ishchenko (Dnipro, Ukraine), D. Stepanskyi (Dnipro, Ukraine)
| |
Eradication treatment of Pseudomonas Aeruginosa in pediatric patients with Cystic Fibrosis.
A. Gulieva (Istanbul, Turkey), C. Yilmaz Yegit (Istanbul, Turkey), M. Yanaz (Istanbul, Turkey), M. Kalyoncu (Istanbul, Turkey), M. Selcuk (Istanbul, Turkey), G. Tastan (Istanbul, Turkey), B. Suzer (Istanbul, Turkey), P. Ergenekon (Istanbul, Turkey), E. Erdem Eralp (Istanbul, Turkey), Y. Gokdemir (Istanbul, Turkey), F. Karakoc (Istanbul, Turkey), B. Karadag (Istanbul, Turkey)
| |
Experience with the use of inhaled carbapenems in a Spanish Cystic Fibrosis Unit
M. Bascuas Arribas (Madrid, Spain), P. Fernández García (Madrid, Spain), V. Sanz Santiago (Madrid, Spain), S. Martín Hernández (Madrid, Spain), A. López Neyra (Madrid, Spain), B. Hernández Millán (Madrid, Spain), J. Alvarez-Coca (Madrid, Spain), M. Camino Serrano (Madrid, Spain), F. Romero Ándujar (Madrid, Spain), J. Villa Asensi (Madrid, Spain), R. Girón Moreno (Madrid, Spain)
| |
Clinical features of SARS-CoV-2/COVID-19 infection in children with cystic fibrosis (CF): A Qatari experience
S. Hamad (Doha, Qatar), H. Kammouh (Doha, Qatar), K. Zahraldin (Doha, Qatar)
| |
Cystic fibrosis competence check: A educational tool for paediatric patients with CF
S. Diemer (Lund, Sweden), K. Wallin (Lund, Sweden), K. Björkman (Lund, Sweden)
| |
The association between the cumulative dose of aminoglycoside exposure and hearing loss in children with cystic fibrosis
C. Yegit (Istanbul, Turkey), P. Ergenekon (Istanbul, Turkey), M. Yanaz (Istanbul, Turkey), A. Guliyeva (Istanbul, Turkey), M. Kalyoncu (Istanbul, Turkey), O. Meral (Istanbul, Turkey), M. Selcuk (Istanbul, Turkey), G. Tastan (Istanbul, Turkey), B. Uzunoglu (Istanbul, Turkey), N. Ozturk (Istanbul, Turkey), F. Toktas (Istanbul, Turkey), A. Atas (Istanbul, Turkey), H. Cetin Kara (Istanbul, Turkey), A. Collak (Istanbul, Turkey), N. Bal (Istanbul, Turkey), O. Gedik (Istanbul, Turkey), Y. Oruc (Istanbul, Turkey), M. Acar (Istanbul, Turkey), R. Dogan (Istanbul, Turkey), E. Gozen Tan (Istanbul, Turkey), H. Molla Kafi (Istanbul, Turkey), N. Karasu (Istanbul, Turkey), Y. Ayhan (Istanbul, Turkey), A. Yumusakhuylu (Istanbul, Turkey), A. Kilinc Sakalli (Istanbul, Turkey), E. Cakir (Istanbul, Turkey), S. Girit (Istanbul, Turkey), Y. Gokdemir (Istanbul, Turkey), E. Erdem Eralp (Istanbul, Turkey), P. Ata (Istanbul, Turkey), A. Ciprut (Istanbul, Turkey), F. Karakoc (Istanbul, Turkey), B. Karadag (Istanbul, Turkey)
| |
Ciliary dyskinesia might be secondary to chronic inflammation in cystic fibrosis
R. Bonhiver (Liege, Belgium), N. Bricmont (Liege, Belgium), M. Pirotte (Liege, Belgium), M. Wuidart (Liege, Belgium), J. Pirson (Liege, Belgium), H. Boboli (Liege, Belgium), R. Louis (Liege, Belgium), M. Seghaye (Liege, Belgium), C. Kempeneers (Liege, Belgium)
| |
CFTR function in respiratory epithelial cell cultures: step to individualize treatments in cystic fibrosis?
J. Grosse-Onnebrink (Münster, Germany), V. Mete (Münster, Germany), H. Omran (Münster, Germany), W. Weber (Münster, Germany)
| |
Prolonged exposure to heat does not affect clinical and biochemical characteristics in patients with cystic fibrosis
P. Anagnostopoulou (NICOSIA, Cyprus), P. Kouis (NICOSIA, Cyprus), K. Pantavou (NICOSIA, Cyprus), A. Michanikou (NICOSIA, Cyprus), A. Matthaiou (NICOSIA, Cyprus), K. Ioakim (NICOSIA, Cyprus), L. Sophocleous (NICOSIA, Cyprus), G. Nikolopoulos (NICOSIA, Cyprus), P. Yiallouros (NICOSIA, Cyprus)
| |
Search for airway-derived miRNA biomarkers in pulmonary exacerbation in children with cystic fibrosis
Z. Stachowiak (Poznan, Poland), B. Narozna (Poznan, Poland), W. Langwinski (Poznan, Poland), I. Wojsyk Banaszak, (Poznan, Poland), K. Jonczyk Potoczna (Poznan, Poland), A. Breborowicz (Poznan, Poland), A. Szczepankiewicz (Poznan, Poland)
| |
Evaluation of performance of Dutch newborn screening program for cystic fibrosis (2016-2020)
M. Bouva (Bilthoven, Netherlands), K. Van Der Ploeg (Leiden, Netherlands), R. Verschoof - Puite (Bilthoven, Netherlands), V. Gulmans (Baarn, Netherlands), J. Gille (Amsterdam, Netherlands), B. Jakobs (Tilburg, Netherlands), M. Heijnen (Bilthoven, Netherlands), K. De Winter - De Groot (Utrecht, Netherlands)
| |
Evaluation of factors affecting bone mineral density in CF patients through CF registry of Turkey
S. Akyan Soydas (ANKARA, Turkey), G. Tugcu (ANKARA, Turkey), M. Gençoglu (ANKARA, Turkey), G. Cinel (ANKARA, Turkey), N. Emiralioglu (ANKARA, Turkey), E. Yalçin (ANKARA, Turkey), N. Kiper (ANKARA, Turkey), V. Sen (DIYARBAKIR, Turkey), D. Ufuk Altintas (DANA, Turkey), H. Çokugras (ISTANBUL, Turkey), A. Ayzit Kilinç (ISTANBUL, Turkey), H. Yazan (ISTANBUL, Turkey), G. Ünal (KONYA, Turkey), A. Yilmaz (KONYA, Turkey), H. Çaglar (KONYA, Turkey), E. Damadoglu (ANKARA, Turkey), I. Irmak (ANKARA, Turkey), E. Demir (IZMIR, Turkey), G. Kartal Öztürk (IZMIR, Turkey), A. Bingöl (ANTALYA, Turkey), E. Basaran (ANTALYA, Turkey), N. Sapan (BURSA, Turkey), A. Aslan (ANKARA, Turkey), P. Asfuroglu (ANKARA, Turkey), K. Harmanci (ESKISEHIR, Turkey), M. Köse (KAYSERi, Turkey), M. Hangül (KAYSERI, Turkey), A. Özdemir (MERSIN, Turkey), G. Özcan (ANKARA, Turkey), Z. Gayretli (TRABZON, Turkey), Ö. Keskin (GAZIANTEP, Turkey), H. Yüksel (MANISA, Turkey), S. Özdogan (ISTANBUL, Turkey), E. Topal (MALATYA, Turkey), G. Çaltepe (SAMSUN, Turkey), D. Can (BALIKESIR, Turkey), P. Korkmaz Ekren (IZMIR, Turkey), M. Kiliç (ELAZIG, Turkey), T. Eyüboglu (ANKARA, Turkey), S. Pekcan (KONYA, Turkey), N. Çobanoglu (ANKARA, Turkey), E. Çakir (ISTANBUL, Turkey), U. Özçelik (ANKARA, Turkey), D. Dogru (ANKARA, Turkey)
| |
Title: Benzbromarone for the treatment of cystic fibrosis (CF) lung disease: a pilot clinical trial.
F. Frederico Friedrich (Porto Alegre (RS), Brazil), L. De Castro E Garcia (Porto Alegre (RS), Brazil), L. Montiel Petry (Porto Alegre (RS), Brazil), M. Pieta (Porto Alegre (RS), Brazil), A. Da Silva Menezes (Porto Alegre (RS), Brazil), L. Braga Bittencourt (Porto Alegre (RS), Brazil), L. Xavier (Porto Alegre (RS), Brazil), M. Brum Antunes (Porto Alegre (RS), Brazil), K. Kunzelmann (Regensburg, Germany), L. Pinto (Porto Alegre (RS), Brazil)
| |
Late Breaking Abstract - Diagnostic testing in people with primary ciliary dyskinesia around the world: where do we stand?
L. Schreck (Bern, Switzerland), E. Pedersen (Bern, Switzerland), I. Cizeau (Saint-Étienne, France), C. Kruljac (Altona, Australia), J. Lucas (Southampton, United Kingdom), M. Goutaki (Bern, Switzerland), C. Kuehni (Bern, Switzerland)
| |